15th Annual

PANTHEON 2018

PRESENTING DiNA™ AWARDS

Friday, November 30 | San Francisco, CA

California Life Sciences AssociationCalifornia Life Sciences Association

Deal of the Year

Bristol Myers Squibb   Nektar Therapeutics
Bristol-Myers Squibb is paying Nektar Therapeutics $1 billion to develop NKTR-214 in combination with Opdivo and Yervoy. All told, Bristol-Myers Squibb is committing $3.6 billion to a deal that gives Nektar the lion’s share of NKTR-214 profits and leaves it some freedom to develop the drug in combination with other assets. The deal is a record-breaker, being the largest biotech licensing fee in history.